NYSEAMERICAN:XXII

22nd Century Group Stock Forecast, Price & News

$4.47

+0.02 (+0.45 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.33

▼

$4.61

50-Day Range

$1.57

▼

$2.54

52-Week Range

$0.55

▼

$6.07

Volume2.66 million shs

Average Volume4.01 million shs

Market Capitalization$681.97 million

P/E RatioN/A

Dividend YieldN/A

Beta1.84

30 days | 90 days | 365 days | Advanced Chart

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

About 22nd Century Group

22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

22nd Century Group, Inc. (NYSEAMERICAN:XXII) Director Sells $597,500.00 in Stock
June 11, 2021 | americanbankingnews.com

22nd Century Group Closes Registered Direct Offering, Raises $40M
June 10, 2021 | msn.com

Four Cannabis Stocks for the Summer of 2021
June 10, 2021 | finance.yahoo.com

22nd Century Announces Closing of $40 Million Common Stock Registered Direct Offering
June 9, 2021 | finance.yahoo.com

22nd Century Announces $40 Million Common Stock Registered Direct Offering
June 7, 2021 | finance.yahoo.com

22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise
June 7, 2021 | finance.yahoo.com

22nd Century Group (NYSEAMERICAN:XXII) Shares Down 5%
June 7, 2021 | americanbankingnews.com

22nd Century Group: Disrupting The Plant-Based Markets With Improved Genetics
June 3, 2021 | markets.businessinsider.com

Is 22nd Century Group a Buy Under $5?
June 1, 2021 | stocknews.com

22nd Century Group (NYSEAMERICAN:XXII) Trading Down 2.4%
May 28, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Cigarettes
Sub-IndustryCannabis
SectorConsumer Staples
Current SymbolNYSEAMERICAN:XXII
Previous SymbolAMEX:XXII
CUSIPN/A
CIKN/A
Webwww.xxiicentury.com
Phone+1-716-2701523
Employees67
Year FoundedN/A

Sales & Book Value

Annual Sales$28.10 million
Price / Sales24.27
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.32 per share
Price / Book13.97

Profitability

EPS (Most Recent Fiscal Year)($0.14)
Net Income$-19,710,000.00
Net Margins-74.35%
Return on Equity-41.31%
Return on Assets-36.03%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares152,567,000
Market Cap$681.97 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

0.56 out of 5 stars

Consumer Staples Sector

239th out of 312 stocks

Cigarettes Industry

7th out of 11 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for 22nd Century Group.

2.8 Community Rank

Outperform Votes
22nd Century Group has received 343 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
22nd Century Group has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
22nd Century Group has received 55.06% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote “Outperform” if you believe XXII will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
22nd Century Group does not currently pay a dividend.
Dividend Growth
22nd Century Group does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 22nd Century Group insiders have sold 1,133.23% more of their company's stock than they have bought. Specifically, they have bought $48,450.00 in company stock and sold $597,500.00 in company stock.
Percentage Held by Insiders
Only 1.80% of the stock of 22nd Century Group is held by insiders.
Percentage Held by Institutions
Only 24.12% of the stock of 22nd Century Group is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for 22nd Century Group are expected to remain at ($0.12) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of 22nd Century Group is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 22nd Century Group is -29.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
22nd Century Group has a P/B Ratio of 13.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

Is 22nd Century Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" 22nd Century Group stock.
View analyst ratings for 22nd Century Group or view top-rated stocks.

What stocks does MarketBeat like better than 22nd Century Group?

Wall Street analysts have given 22nd Century Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 22nd Century Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for 22nd Century Group.

How were 22nd Century Group's earnings last quarter?

22nd Century Group, Inc. (NYSEAMERICAN:XXII) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). 22nd Century Group had a negative trailing twelve-month return on equity of 41.31% and a negative net margin of 74.35%.
View 22nd Century Group's earnings history.

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the following people:

Mr. James A. Mish, Chief Exec. Officer (Age 57, Pay $1.14M)
Mr. Michael J. Zercher, Pres & COO (Age 50, Pay $764.5k)
Mr. John E. Franzino, VP of Admin., CFO & Treasurer (Age 64, Pay $408.9k)
Ms. Mei Kuo, Director of Communications & Investor Relations
Mr. Steven Przybyla, Gen. Counsel & Corp. Sec.
Mr. Henry Sicignano III, M.B.A., MBA, Consultant (Age 53)
Mr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant

Who are some of 22nd Century Group's key competitors?

Some companies that are related to 22nd Century Group include Canopy Growth (WEED), Innovative Industrial Properties (IIPR), Leaf Mobile (LEAF), GrowGeneration (GRWG), OrganiGram (OGI), Emblem (EMC), ICC Labs (ICC), Bioventix (BVXP), KushCo (KSHB), Terra Tech (TRTC), General Cannabis (CANN), Net Savings Link (NSAV), MassRoots (MSRT), Grow Capital (GRWC) and Nemus Bioscience (NMUS).
View all of XXII's competitors.

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include KushCo (KSHB), OrganiGram (OGI), Medical Marijuana (MJNA), Cara Therapeutics (CARA), GB Sciences (GBLX), (CGC), Auxly Cannabis Group (CBWTF), MariMed (MRMD), MassRoots (MSRT) and American Cannabis (AMMJ).

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.74%), Millennium Management LLC (1.32%), Mirae Asset Global Investments Co. Ltd. (0.90%), Geode Capital Management LLC (0.75%), Renaissance Technologies LLC (0.48%) and Quinn Opportunity Partners LLC (0.33%). Company insiders that own 22nd Century Group stock include Clifford B Fleet, James A Mish, Nora B Sullivan and Roger D O'brien.
View institutional ownership trends for 22nd Century Group.

Which major investors are selling 22nd Century Group stock?

XXII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, IHT Wealth Management LLC, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., UBS Group AG, and Bank of New York Mellon Corp.
View insider buying and selling activity for 22nd Century Group or view top insider-selling stocks.

Which major investors are buying 22nd Century Group stock?

XXII stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Quinn Opportunity Partners LLC, HRT Financial LP, Cubist Systematic Strategies LLC, Morgan Stanley, Goldman Sachs Group Inc., and Barclays PLC. Company insiders that have bought 22nd Century Group stock in the last two years include Clifford B Fleet, James A Mish, Nora B Sullivan, and Roger D O'brien.
View insider buying and selling activity for 22nd Century Group or or view top insider-buying stocks.

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $4.47.

How much money does 22nd Century Group make?

22nd Century Group has a market capitalization of $681.97 million and generates $28.10 million in revenue each year. The biotechnology company earns $-19,710,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does 22nd Century Group have?

22nd Century Group employs 67 workers across the globe.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is www.xxiicentury.com.

Where are 22nd Century Group's headquarters?

22nd Century Group is headquartered at 9530 Main St, CLARENCE, NY 14031-1915, United States.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.

This page was last updated on 6/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here